HESTER BIOSCIENCES LTD.

Hester Biosciences Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations and the company's internal code of conduct. The trading window will be shut from July 1, 2026, and will reopen 48 hours after the financial results for the quarter ended June 30, 2026, are made public. This measure is standard practice to prevent insider trading during periods when material non-public information may be available.

Hester Biosciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's operations, employee data, and market presence. Hester Biosciences is primarily engaged in the manufacturing and trading of veterinary vaccines and health products, contributing 100% to its turnover. The company serves both domestic and international markets, with exports accounting for 11% of its total turnover. The report also provides data on its workforce, including permanent employees and workers, and highlights the participation of women in its board and management.

Hester Biosciences Limited has announced that Tuesday, July 14, 2026, has been fixed as the record date. This date will be used to determine shareholders eligible for e-voting at the upcoming 39th Annual General Meeting (AGM) and to receive the proposed final dividend. The dividend is set at INR 11 per equity share, representing 110% of the face value of INR 10 each. This dividend is subject to declaration at the AGM and will be paid after deducting applicable taxes. The company has formally intimated this record date in compliance with SEBI regulations.

Hester Biosciences has issued its 39th Annual Report for the financial year 2025-26 and announced its 39th Annual General Meeting (AGM). The AGM will be held on July 21, 2026, via video conference. The company has also provided details regarding dividend payment, with a cut-off date of July 14, 2026, for entitlement to the final dividend and e-voting. The Annual Report and AGM notice are available on the company's website.

Hester Biosciences Ltd. announced its 39th Annual General Meeting (AGM) will be held on July 21, 2026, at 10:30 a.m. (IST) through Video Conference/Other Audio Visual Means. The company has submitted its Annual Report for the financial year 2025-26 and the AGM notice in compliance with SEBI regulations. The cut-off date for determining members entitled to receive the final dividend and for e-voting eligibility is July 14, 2026. Remote e-voting will start on July 18, 2026, at 9:00 a.m. (IST) and end on July 20, 2026, at 5:00 p.m. (IST). If approved, the dividend will be paid on or after July 28, 2026. The Annual Report and AGM notice have been sent electronically to members, with web links provided for those without registered email addresses.

Hester Biosciences Ltd announced amendments to the loan agreement between its wholly-owned subsidiary, Hester Biosciences Africa Limited, and the Gates Foundation. Key changes include reducing the outstanding loan to USD 5 million, waiving accrued interest, setting no interest on the remaining loan amount, and revising the repayment schedule. Hester India's corporate guarantee continues, with the amendments expected to improve Hester Africa's liquidity and debt servicing.

Hester Biosciences Ltd has submitted applications to BSE Limited and the National Stock Exchange of India Limited on May 19, 2026, seeking a "No Objection" for the re-classification of Mr. Ravin Gandhi and Ms. Bela Gandhi from the Promoter category to the Public category. This action is in accordance with Regulation 31A of the Listing Regulations, following earlier submissions on May 15, 2026, regarding the same re-classification.

Hester Biosciences Ltd has released its corporate presentation for FY 2025-26, as per Regulation 30 of SEBI guidelines. The presentation highlights the company's mission for better human health through healthier animals, its vision to build on a foundation of excellence, and core values including integrity, innovation, passion, discipline, and trust. Key figures mentioned include consolidated revenue of ₹3,325.99 Mn for FY 2025-26.

The Board of Directors of Hester Biosciences Ltd approved the submission of an application to the National Stock Exchange of India Limited and BSE Limited for obtaining a No Objection Certificate for the re-classification requests received from Mr. Ravin Gandhi and Ms. Bela Gandhi (part of Promoters). The board confirmed that Mr. Ravin Gandhi and Ms. Bela Gandhi satisfy the conditions specified under Regulation 31A(3)(b) of the SEBI LODR Regulations and continue to comply with the requirements specified in Regulation 31A (3) and (4) of the Listing Regulations at all times. The re-classification is subject to the receipt of no objection from the Stock Exchanges in terms of Regulation 31A of Listing Regulations.

Hester Biosciences Ltd has received requests from Mr. Ravin Gandhi and Ms. Bela Gandhi, currently classified as Promoters, to be reclassified as Public shareholders. Mr. Ravin Gandhi holds 403,320 equity shares (4.74% of total voting rights) and Ms. Bela Gandhi holds 400,635 equity shares (4.71% of total voting rights). Both individuals have resigned from management roles and assert they no longer exercise control over the company, meeting the conditions for reclassification under SEBI regulations.